A study comparing erlotinib alone with erlotinib intercalated with chemotherapy has failed to demonstrate a clear advantage of the combination strategy when used to treat relapsed patients with non-small-cell lung cancer, Dutch researchers report.
via Med Wire News
via Med Wire News
No comments:
Post a Comment